| PERIOD ENDING | 1-Nov-09 | 2-Aug-09 | | Total Revenue | 428,000 | 363,000 | | Cost of Revenue | 250,000 | 260,000 | | | Gross Profit | 178,000 | 103,000 | | | Operating Expenses | | Research Development | 65,000 | 59,000 | | Selling General and Administrative | 101,000 | 40,000 | | Non Recurring | 2,000 | 4,000 | | Others | 5,000 | (24,000) | | | | Total Operating Expenses | 173,000 | 79,000 | | | | Operating Income or Loss | 5,000 | 24,000 | | | Income from Continuing Operations | | Total Other Income/Expenses Net | (8,000) | 4,000 | | Earnings Before Interest And Taxes | (3,000) | 28,000 | | Interest Expense | 19,000 | 20,000 | | Income Before Tax | (22,000) | 8,000 | | Income Tax Expense | (1,000) | 6,000 | | Minority Interest |
-
|
-
| | | | Net Income From Continuing Ops | (21,000) | 2,000 | | | Non-recurring Events | | Discontinued Operations |
-
|
-
| | Extraordinary Items |
-
|
-
| | Effect Of Accounting Changes |
-
|
-
| | Other Items |
-
|
-
| | | | Net Income | (21,000) | 2,000 | | Preferred Stock And Other Adjustments |
-
|
-
| | | Net Income Applicable To Common Shares | ($21,000) | $2,000 |
|
0.01% Nasdaq 
0.07%
Income Statement
